Novartis Invests $1 Billion in PTC Therapeutics’ Huntington’s Disease Program

Agreement Details:
Novartis has entered into a global license and collaboration agreement with PTC Therapeutics for its mid-phase Huntington's disease program, PTC51812.

Financial Terms:
The agreement includes an upfront payment of $1 billion to PTC Therapeutics, with potential milestone payments of up to $1.9 billion based on development, regulatory, and sales milestones13.

Strategic Impact:
This deal reestablishes Novartis in the R&D race for Huntington's disease treatments and provides significant financial backing for PTC Therapeutics' program2.

Program Status:
The drug is currently in Phase 2 development, indicating it has shown promise in early clinical trials and is moving forward in the development process23.

Sources:

1. https://www.finanznachrichten.de/nachrichten-2024-12/63967811-ptc-therapeutics-inc-ptc-therapeutics-enters-into-a-global-license-and-collaboration-agreement-with-novartis-for-ptc518-huntington-s-disease-progra-008.htm

2. https://www.fiercebiotech.com/biotech/novartis-pays-ptc-1b-upfront-midphase-huntingtons-program-re-establishing-itself-rd-race

3. https://www.biopharmadive.com/news/novartis-ptc-huntingtons-drug-deal-license/734273/